SUN PHARMACEUTICAL INDUSTRIES LTD. - Open Offer to the shareholders of Zenotech Laboratories

Citigroup Global Markets India Private Limited ("Manager to the Offer"), on behalf of Sun Pharmaceutical Industries Limited ("Sun Pharma" / "Acquirer"), has submitted to BSE a Copy of detailed public statement (DPS) to the shareholders of Zenotech Laboratories Limited (Zenotech / Target Company) in respect of the Open Offer (Offer) for acquisition of up to 9,693,332 (Nine Million Six Hundred Ninety Three Thousand Three Hundred Thirty Two) fully paid up equity shares (Shares) representing 28.16% of the fully diluted voting share capital of the Target Company as of the 10th (tenth) working day from the date of closure of the tendering period (Voting Share Capital), in compliance with Regulations 3(1), 4, 5(1) read with Regulations 13(4) and 15(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and subsequent amendments thereto (SEBI (SAST) Regulations) pursuant to the Public Announcement dated April 11, 2014 (PA) which was filed with BSE on April 11, 2014, sent to the Target Company on April 12, 2014, and filed with Securities and Exchange Board of India (SEBI) on April 15, 2014.